- Home
- TOL vs ROIV Comparison
TOL vs ROIV Comparison
Compare TOL & ROIV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TOL
- ROIV
- Stock Information
- Founded
- TOL 1967
- ROIV 2014
- Country
- TOL United States
- ROIV United Kingdom
- Employees
- TOL N/A
- ROIV N/A
- Industry
- TOL Homebuilding
- ROIV Biotechnology: Pharmaceutical Preparations
- Sector
- TOL Consumer Discretionary
- ROIV Health Care
- Exchange
- TOL Nasdaq
- ROIV Nasdaq
- Market Cap
- TOL 13.8B
- ROIV 14.0B
- IPO Year
- TOL N/A
- ROIV N/A
- Fundamental
- Price
- TOL $133.13
- ROIV $20.63
- Analyst Decision
- TOL Buy
- ROIV Strong Buy
- Analyst Count
- TOL 15
- ROIV 8
- Target Price
- TOL $150.87
- ROIV $21.06
- AVG Volume (30 Days)
- TOL 1.0M
- ROIV 8.8M
- Earning Date
- TOL 12-08-2025
- ROIV 11-10-2025
- Dividend Yield
- TOL 0.75%
- ROIV N/A
- EPS Growth
- TOL N/A
- ROIV N/A
- EPS
- TOL 13.61
- ROIV N/A
- Revenue
- TOL $10,876,787,000.00
- ROIV $23,233,000.00
- Revenue This Year
- TOL $0.45
- ROIV N/A
- Revenue Next Year
- TOL N/A
- ROIV $320.50
- P/E Ratio
- TOL $9.83
- ROIV N/A
- Revenue Growth
- TOL 3.26
- ROIV N/A
- 52 Week Low
- TOL $86.67
- ROIV $8.73
- 52 Week High
- TOL $169.52
- ROIV $20.77
- Technical
- Relative Strength Index (RSI)
- TOL 44.65
- ROIV 82.87
- Support Level
- TOL $131.50
- ROIV $19.30
- Resistance Level
- TOL $135.13
- ROIV $20.09
- Average True Range (ATR)
- TOL 3.97
- ROIV 0.61
- MACD
- TOL -0.35
- ROIV 0.10
- Stochastic Oscillator
- TOL 20.17
- ROIV 94.27
About TOL Toll Brothers Inc.
Toll Brothers is the leading luxury homebuilder in the United States with an average sale price well above public competitors'. The company operates in over 60 markets across 24 states and caters to move-up, active-adult, and second-homebuyers. Traditional homebuilding operations represent most of company's revenue. Toll Brothers also builds luxury for-sale and for-rent properties in urban centers across the US. It has its headquarters in Horsham, Pennsylvania.
About ROIV Roivant Sciences Ltd.
Roivant Sciences Ltd is a commercial-stage biopharmaceutical company dedicated to improving the delivery of healthcare to patients. It also incubates discovery-stage companies and health technology startups complementary to its biopharmaceutical business. Its drug candidate VTAMA (tapinarof) is a treatment of plaque psoriasis in adult patients and is in its commercial stage. The other drug candidates in their different stages of development are; Batoclimab, IMVT-1402, Brepocitinib, Namilumab, and others.